DIVERSA Technologies

Our drug delivery technology based on lipidic nanoemulsions allows for safe and physiological intracellular delivery of complex macromolecules (peptides, proteins and nucleic acids) and small hydrophobic molecules. The platform has broad and fresh IP protection and is fully scalable and regulatory compliant. At DIVERSA, we want to bridge the gap between molecules and patients, between drug discovery and clinical application. We want to create new opportunities to improve patients quality of life. Despite the discovery of many new targets and therapeutic molecules in labs around the world, less than 3% of them will make it to clinical stages. Most of...

Nanotechnology,intracellular delivery,biotechnology,drug delivery system,small molecule delivery,protein delivery,peptide delivery,mrna delivery,sirna delivery,and dna delivery

Diversa technologies operates in the Biotechnology research industry.

Diversa technologies's revenue is 11m - 100m

Diversa technologies has 11 - 50 employees.